扫码下载
BTC $61,761.70 +1.46%
ETH $1,606.00 +2.97%
BNB $585.67 +2.54%
XRP $1.12 +3.89%
SOL $64.26 +3.42%
TRX $0.3248 +1.71%
DOGE $0.0839 +4.84%
ADA $0.1613 +5.76%
BCH $224.02 +8.00%
LINK $7.62 +5.45%
HYPE $59.43 +0.51%
AAVE $62.58 +4.40%
SUI $0.7517 +9.92%
XLM $0.2117 +9.40%
ZEC $386.86 +4.60%
BTC $61,761.70 +1.46%
ETH $1,606.00 +2.97%
BNB $585.67 +2.54%
XRP $1.12 +3.89%
SOL $64.26 +3.42%
TRX $0.3248 +1.71%
DOGE $0.0839 +4.84%
ADA $0.1613 +5.76%
BCH $224.02 +8.00%
LINK $7.62 +5.45%
HYPE $59.43 +0.51%
AAVE $62.58 +4.40%
SUI $0.7517 +9.92%
XLM $0.2117 +9.40%
ZEC $386.86 +4.60%

翰宇药业与数字资产平台 Ku­C­o­in 签署战略合作意向书,股价拉升涨停

2025-08-04 14:48:33
收藏

ChainCatcher 消息,翰宇药业(300199.SZ)午后拉升涨停,报价 24.32 元,股价创 2022 年 12 月以来新高。

消息面上,翰宇药业与数字资产平台 Ku­C­o­in 正式签署战略合作意向书,双方拟共同探索在香港共同推进中国内地首个以“创新药研发未来收益权”为底层资产的 RWA(Re­al Wo­r­ld As­s­et)代币化试点项目。

根据协议,翰宇药业将以其在 GLP-1 类多肽重磅药物领域的技术积累与研发管线为基础资产,Ku­C­o­in 则将发挥其在区块链技术、RWA 全流程解决方案和全球合规资源方面的优势,为该项目提供链上映射、资产通证化、交易撮合、收益分配等一体化支持。(格隆汇)

app_icon
ChainCatcher 与创新者共建Web3世界